FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

SHANGHAI, China, Jan. 25, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that U.S. Food and Drug Administration (FDA) has granted toripalimab Fast Track designation for the first-line treatment of mucosal melanoma. […] Lire la suite »

Zehn führende BioPharma-Unternehmen geben die Gründung von Accumulus Synergy zur Entwicklung einer globalen Plattform für den Datenaustausch bekannt

Finanziert von Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi und Takeda Die Unternehmen unterstützen die Einführung einer cloudbasierten Plattform mit dem Potenzial, Kommunikation und Datenaustausch zwischen Biopharmaindustrie und Gesundheitsbehörden zu revolutionieren BURLINGAME, Kalifornien, Jan. 22, 2021 (GLOBE NEWSWIRE) — Zehn der weltweit führenden Biopharmaunternehmen haben heute […] Lire la suite »

Dix sociétés biopharmaceutiques de premier plan annoncent la création d’Accumulus Synergy pour développer une plateforme mondiale de partage de données

Financée par Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi et Takeda Ces sociétés vont soutenir le déploiement d’une plateforme basée sur le cloud avec le potentiel de transformer la manière dont l’industrie biopharmaceutique communique et échange des informations avec les autorités sanitaires du monde entier. BURLINGAME, […] Lire la suite »

XBiotech kündigt medizinischen Beirat für zerebrovaskuläre Erkrankungen und die Entwicklung einer neuen Schlaganfalltherapie an

AUSTIN, Texas, Jan. 20, 2021 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) hat heute die erste Sitzung seines medizinischen Beirats für zerebrovaskuläre Erkrankungen (Cerebrovascular Medical Advisory Board, CMAB) angekündigt.Der CMAB besteht aus wichtigen Meinungsbildnern, die sich auf zerebrovaskuläre Erkrankungen wie den ischämischen Schlaganfall spezialisiert haben. Dieser ist die weltweit dritthäufigste […] Lire la suite »

XBiotech annonce le Comité consultatif médical sur les maladies cérébrovasculaires et le développement de nouveaux traitements relatifs aux accidents vasculaires cérébraux

AUSTIN, Texas, 20 janv. 2021 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd’hui la première réunion de son Comité consultatif médical sur les maladies cérébrovasculaires (CMAB). Le CMAB est composé de leaders d’opinion clés spécialisés dans les maladies cérébrovasculaires, y compris les accidents vasculaires cérébraux (AVC) ischémiques, qui […] Lire la suite »

Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis

–EDP1815 was well tolerated, and showed clinically meaningful and consistent changes in all measured physician-reported outcomes – –Improvements in patient-reported outcomes in DLQI and POEM, including itch––EASI50 benchmark reached in 44% of patients treated with EDP1815 compared to 0% in placebo group at day 70––Phase 2 atopic dermatitis trial initiation in […] Lire la suite »

Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference on 21 January 2021 at 3 pm ET/8 pm GMT

NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company“), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO, Dr. Kunwar Shailubhai, will participate in a fireside […] Lire la suite »

Tiziana Life Sciences plc (“Tiziana” or the “Company”) – AIM Delisting and Admission to the Standard Listing Segment of Main Market

NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today provided a further update with respect to the cancellation of admission of its […] Lire la suite »

Biophytis Announces Public Filing of a Registration Statement for Proposed Initial Public Offering in the United States

PARIS and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) — Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients […] Lire la suite »

OKYO Pharma Limited (“OKYO” or the “Company”) – OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS

LONDON and BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) — OKYO (LSE: OKYO; OTCQB: EMMLF), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, announces that it has today submitted a patent application for the potential […] Lire la suite »

Taconic Biosciences erweitert Portfolio an Tiermodellen für die Immunonkologie

RENSSELAER, New York, Jan. 18, 2021 (GLOBE NEWSWIRE) — Taconic Biosciences, ein weltweit führender Anbieter von Tiermodellen für die Arzneimittelforschung, gibt die Erweiterung seines Portfolios für die Immunonkologie bekannt.   Die Immunonkologie hat in der Forschung besondere Priorität, weil sie das körpereigene Immunsystem dazu nutzt, bestimmte Krebsarten effektiv zu behandeln. Syngene […] Lire la suite »

Taconic Biosciences étend son portefeuille de modèles animaux pour l’immuno-oncologie

RENSSELAER, NY, 18 janv. 2021 (GLOBE NEWSWIRE) — Taconic Biosciences, leader mondial parmi les fournisseurs de modèles animaux destinés à la recherche pharmaceutique, annonce un élargissement de son portefeuille d’immuno-oncologie.   L’immuno-oncologie est une priorité de recherche de premier plan parce qu’elle utilise le système immunitaire du corps pour traiter efficacement […] Lire la suite »

Taconic Biosciences Expands Immuno-oncology Animal Model Portfolio

RENSSELAER, N.Y., Jan. 18, 2021 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces an expansion of its immuno-oncology portfolio.   Immuno-oncology is a leading research priority because it uses the body’s own immune system to effectively treat some types of cancer. Syngeneic tumor […] Lire la suite »

RoosterBio arbeitet mit Sartorius zusammen, um Herstellungskapazität für Zell- und Gentherapien auszubauen

FREDERICK, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) — RoosterBio Inc., ein führender Anbieter von Working-Zellbanken mit humanen mesenchymalen Stamm-/Stromazellen (hMSC) und hochentwickelten Medien- und hMSC-Bioprozesssystemen, hat heute die Unterzeichnung einer Vereinbarung zur strategischen Zusammenarbeit mit Sartorius bekanntgegeben, einem führenden internationalen Partner im Bereich der biowissenschaftlichen Forschung und der biopharmazeutischen Industrie.Die […] Lire la suite »

RoosterBio s’associe à Sartorius pour faire progresser la fabrication de thérapies cellulaires et géniques

FREDERICK, Maryland, 14 janv. 2021 (GLOBE NEWSWIRE) — RoosterBio Inc., un fournisseur de premier plan de banques de cellules de travail diffusant des cellules souches/stromales mésenchymateuses humaines (hMSC), de milieux très techniques et de systèmes de biotraitement hMSC, annonce aujourd’hui la signature d’une collaboration stratégique avec Sartorius, un partenaire international […] Lire la suite »

Tiziana Life Sciences to Present at Biotech Showcase Digital 2021

NEW YORK and LONDON, Jan. 11, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that it is participating in Biotech Showcase™ 2021 and providing an on-demand company presentation. […] Lire la suite »

Cyclolab and EpiPharma Form Joint Venture company Targetrin Therapeutics to Develop and Commercialize novel conjugated Cyclodextrin – Peptide drugs

SZEGED, Hungary and BUDAPEST, Hungary, Jan. 11, 2021 (GLOBE NEWSWIRE) — Cyclolab, the oldest, world renowned cyclodextrin research, development and manufacturing company, and EpiPharma, a bio-pharmaceutical services and peptide drug development company, today announced that the companies have signed an agreement to form a joint venture specialty pharmaceutical company to […] Lire la suite »

Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)

The global Phase 4 RESPOND study will evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical response to Zolgensma Clinical and real-world experience have reported that some patients previously treated with Zolgensma have also been treated with SPINRAZA1,2,3,4 Biogen remains committed to exploring the potential of […] Lire la suite »

Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine

Advance Purchase Agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate Initial doses expected to be delivered as early as mid-2021 GAITHERSBURG, Md., Jan. 07, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has executed […] Lire la suite »